Adalat: A Comprehensive Review

P. R. Lichtlen; A. Reale

ISBN 10: 0387540334 / ISBN 13: 9780387540337

Published by Springer, USA, 1991

About this Item

0387540334. Blue cloth hardcover, from closed pharmaceutical company library, with usual labels, marks. Lending record shows this book has never been borrowed. 237 pages, index, illustrated with charts, tables and diagrams. This volume documents the Adalat story, from its beginnings in research and development to its pioneering role in new areas of pharmacological treatment. Adalat is effective in treating hypertension, acute neurology, dementia, atherosclerosis and heart failure. This book surveys a chapter in the history of cardiovascular research. Sections include: Adalat History; Hypertension; Coronory Heart Disease; Coronory Atherosclerosis; Outlook, Adalat: Its Future. Contents appears unread, clean, tight and bright.

Seller Inventory # 031941

Bibliographic Details

• Title: Adalat: A Comprehensive Review
• Publisher: Springer, USA
• Publication Date: 1991
• Language: English
• ISBN 10: 0387540334
• ISBN 13: 9780387540337
• Binding: Hardcover
• Condition: Very Good
• Dust Jacket Condition: Very Good
• Book Type: Book
• Seller catalogs:
  • Medical Research

About this title

Synopsis

As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri­ can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world­ wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar­ macological revolution, which started out from whole animal models and progres­ sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd­ ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge.